Replies to post #94 on Coherus BioSciences Inc (CHRS)

[DewDiligence]

CHRS had its 4Q17 earnings release and CC yesterday and said that the FDA accepted CHRS' proposed assay to measure immunogenicity of the company's Neulasta FoB.

I'm surprised the stock is up so much today. FDA acceptance of the proposed assay is not the same as FDA acceptance of the assayed immunogenicity data, which is the issue of consequence for this program.